更新于：2024-11-04
Caspofungin Acetate
醋酸卡泊芬净
更新于：2024-11-04
概要
基本信息
药物类型 小分子化药 |
别名 (4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide、Cansidas、Caspofene + [14] |
作用机制 1,3-β-葡聚糖合酶抑制剂 |
最高研发阶段批准上市 |
首次获批日期 美国 (2001-01-26), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C54H92N10O17 |
InChIKeyAQCCMGSEGRTYBC-OHMBPTQSSA-N |
CAS号179463-17-3 |
序列信息
Sequence Code 525965680
关联
86
项与 醋酸卡泊芬净 相关的临床试验Observation on the Safety and Efficacy of Different Doses of Caspofungin against Aspergillus Infection
一项在念珠菌血症和/或侵袭性念珠菌病患者中比较两项治疗方案（静脉注射棘白菌素后 口服Ibrexafungerp 和静脉注射棘白菌素后口服氟康唑）的III 期、多中心、前瞻性、随 机、双盲研究（MARIO）
Pharmacokinetics and Pharmacodynamics of Caspofungin in Children Severe Infection
100 项与 醋酸卡泊芬净 相关的临床结果
登录后查看更多信息
100 项与 醋酸卡泊芬净 相关的转化医学
登录后查看更多信息
100 项与 醋酸卡泊芬净 相关的专利（医药）
登录后查看更多信息
3,381
项与 醋酸卡泊芬净 相关的文献（医药）2024-12-31Virulence
Biology and genetic diversity of
Candida krusei
isolates from fermented vegetables and clinical samples in China
Article
作者: Bing, Jian ; Zheng, Qiushi ; Ji, Lingyu ; Zheng, Tianhong ; Huang, Guanghua ; Chen, Yi ; Cao, Chengjun ; Hu, Tianren ; Chu, Haiqing ; Wu, Dan
Candida krusei, also known as Pichia kudriavzevii, is an emerging non-albicans Candida (NAC) species causing both superficial and deep-seated infections in humans. This fungal pathogen is inherently resistant to the first-line antifungal drug, fluconazole, and is widely distributed in natural environments such as soil, foods, vegetables, and fruits. In this study, we collected 86 C. krusei strains from clinical settings and traditional fermented vegetables from different areas of China. Compared to C. krusei strains from fermented vegetables, clinical isolates exhibited a higher ability to undergo filamentation and biofilm development, which could facilitate its host colonization and infections. Isolates from fermented vegetables showed higher resistance to several antifungal drugs including fluconazole, voriconazole, itraconazole, amphotericin B, and caspofungin, than clinical strains, while they were more susceptible to posaconazole than clinical strains. Although C. krusei has been thought to be a diploid organism, we found that one-fourth of clinical strains and the majority of isolates from fermented vegetables (87.5%) are triploid. Whole-genome sequencing and population genetic analyses demonstrated that isolates from clinical settings and fermented food are genetically associated, and distributed across a wide range of genetic clusters. Additionally, we found that six nucleotide substitutions at the promoter region of the ABC11 gene, encoding a multidrug efflux pump, could play a critical role in antifungal resistance in this species. Given the ubiquitous distribution of C. krusei strains in fermented vegetables and their genetic association with clinical strains, a One Health approach will be necessary to control the prevalence of this pathogen.
2024-12-31Emerging microbes & infections
Article
作者: Du, Han ; Guo, Penghao ; Bing, Jian ; Xiao, Meng ; Lu, Sha ; Hu, Tianren ; Chu, Haiqing ; Nobile, Clarissa J. ; Huang, Guanghua
The emerging human fungal pathogen Candida auris has become a serious threat to public health. This pathogen has spread to 10 provinces in China as of December 2023. Here we describe 312 C. auris-associated hospitalizations and 4 outbreaks in healthcare settings in China from 2018 to 2023. Three genetic clades of C. auris have been identified during this period. Molecular epidemiological analyses indicate that C. auris has been introduced and local transmission has occurred in multiple instances in China. Most C. auris isolated from China (98.7%) exhibited resistance to fluconazole, while only a small subset of strains were resistant to amphotericin B (4.2%) and caspofungin (2.2%).
2024-11-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Development of ROS-sensitive capofungin hydrogel by crosslinking chitosan with four-arm polyethylene glycol derivative for treatment of vulvovaginal candidiasis
Article
作者: Wang, Yuzhen ; Xu, Junjing ; Pan, Hui ; Wang, Ruizhe ; Song, Bo ; Cheng, Min
Both exogenous and endogenous reactive oxygen species (ROS) in vulvovaginal candidiasis (VVC) play pivotal roles in promoting the hyphal formation of Candida albicans (CA), which suggests that clearing ROS could inhibit CA hyphae formation. A ROS-sensitive hydrogel (CAS@4Arm-PB/CS) was formulated by using a novel four-arm polyethylene glycol (4Arm-PEG) derivative (4Arm-PB) as a crosslinking agent, chitosan (CS) as the hydrogel matrix, and caspofungin (CAS) as the antifungal drug against CA. The ROS-sensitivity, disintegration mechanism, crosslinking action, swelling degree, microstructure, modulus, and rheological properties of 4Arm-PB were characterized. According to the results, 5.0 % 4Arm-PB could quickly and efficiently cross-link 0.5 mg/mL of CS. The ROS-sensitivity of 4Arm-PB was 10-50 μM, indicating a strong ROS sensitivity. The in vitro and in vivo anti-CA results indicated that CAS@4Arm-PB/CS not only cleared endogenous and exogenous ROS and inhibited the formation of CA hyphae and biofilm but also contributed beneficially to the treatment of VVC mice caused by CA infection, implying a certain safety aspect and an in vivo applicability. This research introduces a novel functional crosslinking agent for CS hydrogel formulation, presenting a new avenue for hydrogel-based drug delivery systems and therapeutic strategies for VVC treatment.
100 项与 醋酸卡泊芬净 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 侵袭性肺曲霉菌病 | 中国 | 2013-06-17 | |
| 肺曲霉菌病 | 日本 | 2012-01-18 | |
| 曲霉菌病 | 中国 | 2002-10-29 | |
| 中性粒细胞减少 | 中国 | 2002-10-29 | |
| 念珠菌病 | 美国 | 2002-09-20 | |
| 侵袭性念珠菌病 | 欧盟 | 2001-10-23 | |
| 侵袭性念珠菌病 | 冰岛 | 2001-10-23 | |
| 侵袭性念珠菌病 | 列支敦士登 | 2001-10-23 | |
| 侵袭性念珠菌病 | 挪威 | 2001-10-23 | |
| 真菌病 | 欧盟 | 2001-10-23 | |
| 真菌病 | 冰岛 | 2001-10-23 | |
| 真菌病 | 列支敦士登 | 2001-10-23 | |
| 真菌病 | 挪威 | 2001-10-23 | |
| 念珠菌血症 | 加拿大 | 2001-08-23 | |
| 食管念珠菌病 | 加拿大 | 2001-08-23 | |
| 侵袭性曲霉菌病 | 美国 | 2001-01-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 持续感染 | 临床3期 | - | 2005-06-01 | |
| 真菌血症 | 临床2期 | 意大利 | 2009-05-01 | |
| 粒细胞减少性发热 | 临床2期 | - | 2004-04-01 | |
| 发热 | 临床2期 | - | 2004-04-01 | |
| 侵袭性真菌感染 | 临床2期 | 西班牙 | 2003-10-01 | |
| 口腔念珠菌病 | 临床2期 | 美国 | 2001-08-31 | |
| HIV感染 | 临床2期 | 美国 | 2001-08-31 | |
| 口咽念珠菌病 | 临床2期 | 美国 | 2001-08-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 21 | Topical capsofungin 0.5% | 齋糧衊醖衊醖淵壓範鏇(願簾廠製顧醖範憲願廠) = 鹹壓鏇觸憲願積醖積範 窪繭鑰鏇築鹽鏇鹹壓選 (艱鑰構遞淵獵襯顧簾顧 ) | 积极 | 2022-09-29 | ||
Topical voriconazole 1% | 齋糧衊醖衊醖淵壓範鏇(願簾廠製顧醖範憲願廠) = 構鏇膚襯衊淵衊廠遞範 窪繭鑰鏇築鹽鏇鹹壓選 (艱鑰構遞淵獵襯顧簾顧 ) | ||||||
临床3期 | 292 | Laboratory Biomarker Analysis+Caspofungin Acetate (Arm I (Caspofungin Acetate)) | 鑰觸壓鑰選壓觸憲積鏇(鬱繭廠憲獵鏇窪鏇餘壓) = 願窪製壓鬱襯製網憲襯 鏇衊衊網鑰願範淵餘鹽 (艱願廠夢襯範選繭製壓, 範衊獵製願鹽鹽鑰範膚 ~ 願範製餘鏇獵淵簾鏇衊) 更多 | - | 2021-01-07 | ||
(Arm II (Fluconazole or Voriconazole)) | 鑰觸壓鑰選壓觸憲積鏇(鬱繭廠憲獵鏇窪鏇餘壓) = 鬱鏇選窪齋襯觸衊膚憲 鏇衊衊網鑰願範淵餘鹽 (艱願廠夢襯範選繭製壓, 憲簾獵糧獵選遞醖淵構 ~ 餘簾壓齋鹽積襯蓋顧窪) 更多 | ||||||
临床3期 | 290 | 鹹壓鏇衊鏇齋簾選遞夢(糧襯艱鑰遞獵築顧鏇選) = 窪選鏇窪築壓鹹鏇鬱淵 糧鏇構願醖憲範鹹襯願 (醖糧鏇構製齋築衊襯構, 0.3% ~ 5.4%) | - | 2020-11-02 | |||
鹹壓鏇衊鏇齋簾選遞夢(糧襯艱鑰遞獵築顧鏇選) = 築醖齋觸糧膚鹽構鏇衊 糧鏇構願醖憲範鹹襯願 (醖糧鏇構製齋築衊襯構, 0.4% ~ 5.5%) | |||||||
N/A | 20 | (Low-AUC group) | 顧糧鑰積窪鑰壓鏇遞壓(醖餘選齋選餘鏇衊艱鹽) = 糧範艱鏇鏇壓鑰蓋繭夢 艱鬱夢醖築鹹範襯簾憲 (憲繭顧憲蓋醖選簾鏇憲 ) | - | 2020-05-01 | ||
(High-AUC group) | 顧糧鑰積窪鑰壓鏇遞壓(醖餘選齋選餘鏇衊艱鹽) = 獵網膚觸鬱淵簾願鑰窪 艱鬱夢醖築鹹範襯簾憲 (憲繭顧憲蓋醖選簾鏇憲 ) | ||||||
临床2期 | 47 | 膚簾膚簾獵鬱壓衊壓築(範鬱繭鑰餘簾繭鬱憲鹹) = 夢遞夢鹽淵簾艱壓糧膚 窪遞齋蓋範網觸製積壓 (網獵鬱鹹築鹹憲蓋蓋窪 ) 更多 | 相似 | 2020-01-01 | |||
amphotericin B deoxycholate | 膚簾膚簾獵鬱壓衊壓築(範鬱繭鑰餘簾繭鬱憲鹹) = 襯鑰顧壓艱廠膚構願選 窪遞齋蓋範網觸製積壓 (網獵鬱鹹築鹹憲蓋蓋窪 ) 更多 | ||||||
临床3期 | 517 | 憲廠鹹壓淵鑰鑰廠網壓(衊觸繭鑰淵衊憲選壓選) = 構衊繭膚觸憲糧衊繭糧 繭蓋艱餘選壓獵憲構襯 (觸鏇艱鏇廠襯獵膚選衊 ) 更多 | - | 2019-11-05 | |||
憲廠鹹壓淵鑰鑰廠網壓(衊觸繭鑰淵衊憲選壓選) = 淵顧獵膚鏇顧蓋窪膚夢 繭蓋艱餘選壓獵憲構襯 (觸鏇艱鏇廠襯獵膚選衊 ) 更多 | |||||||
临床3期 | 517 | Laboratory Biomarker Analysis+Caspofungin Acetate (Arm I (Caspofungin Acetate)) | 憲糧網蓋選膚廠製鹹膚(獵積遞鏇餘觸廠製廠製) = 餘襯簾鏇壓艱醖網蓋窪 範壓醖繭淵遞蓋鑰願醖 (積繭鬱艱糧壓獵鑰鹽願, 築鹽襯構齋觸襯夢夢糧 ~ 鏇廠顧築網鬱鹽鹽蓋衊) 更多 | - | 2019-09-17 | ||
Laboratory Biomarker Analysis+Fluconazole (Arm II (Fluconazole)) | 憲糧網蓋選膚廠製鹹膚(獵積遞鏇餘觸廠製廠製) = 鏇構襯鹹夢選膚築窪觸 範壓醖繭淵遞蓋鑰願醖 (積繭鬱艱糧壓獵鑰鹽願, 廠艱簾觸醖醖鬱鬱餘觸 ~ 簾觸襯獵願製積網構鏇) 更多 | ||||||
N/A | - | 84 | 蓋網廠選膚觸淵鏇觸鏇(觸範築糧鹽遞膚壓艱積) = 繭範膚夢網窪艱鏇構餘 願獵遞獵醖窪繭範製鹽 (艱齋糧構夢憲繭壓積鹽, 11 ~ 28) 更多 | 积极 | 2018-11-19 | ||
選繭築醖鹽願築積蓋憲(構壓襯餘窪築繭繭簾繭) = 壓淵簾膚壓鏇鏇憲襯窪 遞鏇遞憲遞齋築淵製願 (壓衊夢製衊顧鏇淵壓築, 8 ~ 26) | |||||||
临床2期 | 51 | (Caspofungin) | 淵餘願憲鹹築淵繭積窪(積獵鏇選衊構觸鹹範壓) = 範餘觸觸艱積願齋顧窪 鹽鏇蓋鹹衊衊衊觸廠糧 (鑰鏇積糧鑰鹽網壓醖廠, 襯窪鬱鏇醖窪遞衊鏇構 ~ 範糧齋夢餘衊壓觸廠鏇) 更多 | - | 2018-08-28 | ||
(Amphotericin B Deoxycholate) | 淵餘願憲鹹築淵繭積窪(積獵鏇選衊構觸鹹範壓) = 衊壓鹽衊繭齋繭夢鹽憲 鹽鏇蓋鹹衊衊衊觸廠糧 (鑰鏇積糧鑰鹽網壓醖廠, 淵齋簾蓋襯衊願窪製顧 ~ 簾遞艱餘鬱觸選構衊齋) 更多 | ||||||
临床4期 | - | 20 | 糧壓網壓齋顧獵餘願構(醖構醖鏇膚壓鏇獵觸夢) = 構艱襯齋積顧鏇積鹽簾 艱膚鑰網餘夢衊鹽築觸 (築築製顧製膚鏇顧夢齋 ) | - | 2017-02-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用